염증성장질환 치료 시장 : 기회, 성장 촉진요인, 산업 동향 분석과 예측(2024-2032년)

Global Inflammatory Bowel Disease Treatment Market is projected to achieve a 6.1% CAGR from 2024 to 2032, catapulted by the prevalence of IBD and growing awareness of this condition. As per the U.S. National Institutes of Health (NIH) report, global spending on biotechnology R and D reached USD 400 billion in 2023. This upsurge in investment supports the development of innovative therapies for IBD, such as biologics and targeted treatments. The expanding patient population and the need for personalized treatment options are creating a positive industry outlook.

Advances in biotechnology and pharmaceuticals have resulted in innovative therapies that are positively improving patient outcomes. Additionally, growing investment in research and development by pharmaceutical companies and a surge in collaborations between research institutions and biotech firms are accelerating inflammatory bowel disease treatment market growth.

The inflammatory bowel disease treatment industry is sorted based on treatment type, drug class, route of administration, distribution channel, and region.

The ulcerative colitis segment will experience a decent growth rate through 2032, due to an increase in the number of diagnosed cases and growing awareness of the condition. Ulcerative colitis, a chronic inflammatory condition affecting the colon, often requires specialized management strategies, leading to heightened demand for targeted treatments and therapeutic advancements. As healthcare providers and patients seek more effective and tailored treatment options to manage symptoms and improve quality of life, the focus on ulcerative colitis has intensified, amplifying segment growth. Enhanced diagnostic techniques and patient education are contributing to the increased demand.

By 2032, the e-commerce segment will hold a significant inflammatory bowel disease treatment market share, owing to improved patient accessibility and convenience. Online platforms facilitate the direct purchase of medications and treatment-related products, allowing for easier access to a wide range of specialty and niche treatments. This increased availability is beneficial for patients in remote or underserved areas, where access to physical pharmacies may be limited. E-commerce channels offer a streamlined purchasing process and provide detailed information and patient reviews, helping consumers make informed decisions.

Europe inflammatory bowel disease treatment market will record an impressive growth rate over the study period, bolstered by the increasing healthcare expenditure enhancing the affordability of advanced treatments. The strong regulatory framework in the region supports the development and approval of new therapies, fostering innovation in the treatment landscape. The rising prevalence of IBD in Europe, coupled with greater public awareness and early diagnosis, is leading to a higher demand for effective management solutions. A well-established network of research institutions and pharmaceutical companies is accelerating the development of novel treatments, aiding market growth.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of IBD
    • 3.2.1.2 Technological advancements
    • 3.2.1.3 Favorable reimbursement policies
    • 3.2.1.4 Growing awareness and early diagnosis of IBD symptoms
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Stringent regulatory scenario
    • 3.2.2.2 High cost of treatment
• 3.3 Growth potential analysis
• 3.4 Reimbursement scenario
• 3.5 Regulatory landscape
• 3.6 Epidemiological scenario
• 3.7 Future market trends
• 3.8 Pipeline analysis
• 3.9 Pricing analysis, 2023
• 3.10 Brand analysis
• 3.11 Porter's analysis
• 3.12 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Crohn's disease
• 5.3 Ulcerative colitis

Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 TNF inhibitors
• 6.3 Aminosalicylates
• 6.4 Corticosteroids
• 6.5 IL inhibitors
• 6.6 JAK inhibitors
• 6.7 Anti-integrin
• 6.8 Other drug classes

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Injectable
• 7.3 Oral

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacy
• 8.3 Retail pharmacy
• 8.4 Online pharmacy

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 AbbVie Inc
• 10.2 Amgen Inc.
• 10.3 Biogen
• 10.4 CELLTRION INC
• 10.5 Dr Falk Pharma UK Ltd
• 10.6 Ferring B.V.
• 10.7 Ferring B.V.
• 10.8 Johnson and Johnson
• 10.9 Lilly
• 10.10 Novartis AG
• 10.11 Pfizer Inc
• 10.12 Takeda Pharmaceutical Company Limited
• 10.13 Tillotts Pharma AG
• 10.14 UCB Group